Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors
- 29 February 2012
- journal article
- research article
- Published by Elsevier BV in Antiviral Research
- Vol. 93 (2), 245-252
- https://doi.org/10.1016/j.antiviral.2011.12.003
Abstract
No abstract availableKeywords
Funding Information
- NIH/NIAID (AI066160)
- NIAID (1 T32 AI065396-01)
- National Library of Medicine Training Program (T15 LM007093)
This publication has 33 references indexed in Scilit:
- Anthracene-based inhibitors of dengue virus NS2B–NS3 proteaseAntiviral Research, 2011
- An AlphaScreen®-Based Assay for High-Throughput Screening for Specific Inhibitors of Nuclear ImportSLAS Discovery, 2011
- Novel Dengue Virus-Specific NS2B/NS3 Protease Inhibitor, BP2109, Discovered by a High-Throughput Screening AssayAntimicrobial Agents and Chemotherapy, 2011
- Structure-based discovery of dengue virus protease inhibitorsAntiviral Research, 2009
- In vitro genotoxic and cytotoxic effects of ivermectin and its formulation ivomec® on Chinese hamster ovary (CHOK1) cellsJournal of Hazardous Materials, 2009
- Is Paromomycin an Effective and Safe Treatment against Cutaneous Leishmaniasis? A Meta-Analysis of 14 Randomized Controlled TrialsPLoS Neglected Tropical Diseases, 2009
- Substrate Inhibition Kinetic Model for West Nile Virus NS2B-NS3 ProteaseBiochemistry, 2008
- Characterization of the West Nile virus protease substrate specificity and inhibitorsThe International Journal of Biochemistry & Cell Biology, 2007
- Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agentMolecular Cancer Therapeutics, 2006
- Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sitesBiochemical and Biophysical Research Communications, 2005